Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study
Authors:
- 3 June 2016
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (8) , 1336-1341
Abstract
Background: There is limited information about active tuberculosis (TB) occurring in psoriasis patients treated with Tumor necrosis factor (TNF) antagonists.Objective: To describe the clinical characteristics of TB in psoriasis patients treated with TNF antagonists.Methods: Nationwide retrospective study of psoriasis patients having experienced TB. Cases of TB were collected via three methods: search in the national pharmacosurveillance database, questionnaire to members of the French psoriasis research group, the college of French dermatology professors. We collected demographic data, TNF antagonist used, screening for latent tuberculosis infection, median time between TNF antagonists introduction and first symptoms, tests used for diagnosing TB infection, clinical features of tuberculosis and outcome.Results: Eight centres reported 12 cases of TB between 2006 and 2014. They were nine men and three women with mean age of 49 years. All patients had adequate screening for latent tuberculosis. Three patients had stayed in endemic areas, three reported contact with a patient with TB. Tuberculosis presentation was extrapulmonary in 10 patients. Seven patients were treated with infliximab, four with adalimumab and one with certolizumab. The median time between TNF antagonist introduction and first symptoms of tuberculosis was 23.4 weeks (2–176). Six of the 12 patients had a positive direct examination and/or positive culture for Mycobacterium tuberculosis. Histological samples of affected organs taken from seven patients showed granulomatous inflammation in six, with caseating necrosis in five. Two of the 12 patients died of disseminated TB.Conclusion: This study shows tuberculosis in patients treated with TNF antagonists still occurs despite adherence to tuberculosis prevention guidelines. Prophylactic measures do not fully prevent the occurrence of tuberculosis. Rapid initiation of effective anti‐tuberculosis treatment is important even in patients with negative mycobacteriological examination presenting with suggestive symptoms and organ involvement.Keywords
This publication has 22 references indexed in Scilit:
- Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedsideJournal of Microbiology, Immunology and Infection, 2014
- Traitement des infections tuberculeuses latentesRevue des Maladies Respiratoires, 2012
- Interferon-γ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysisThe Journal of Infectious Diseases, 2011
- Interferon gamma release assays: principles and practiceEnfermedades Infecciosas y Microbiología Clínica, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2008
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- treatmentThorax, 2005
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001